The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MONARCH 2: subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer.
 
Patrick Neven
Honoraria - Lilly (Inst)
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - Kom op tegen Kanker
 
Stephen R. D. Johnston
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Puma Biotechnology
Speakers' Bureau - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; Roche
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
 
Masakazu Toi
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Genomic Health; Konica Minolta; Kyowa Hakko Kirin; Lilly; Novartis; Pfizer; Shimadzu; Taiho Pharmaceutical; TAKEDA; Yakult Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Konica Minolta; Kyowa Hakko Kirin
Speakers' Bureau - AstraZeneca; Lilly; Pfizer
Research Funding - AFI technology; Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Japan Breast Cancer Research Group; Kyoto Breast cancer Research Network; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Shimadzu; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - JP 2017-143763 WO2017/131162A1 (Inst); PCT/JP2016/004374 (Inst)
Travel, Accommodations, Expenses - Eisai; Takeda
Other Relationship - Japan Breast Cancer Research Group; Japan Breast Cancer Research Group; Kyoto Breast Cancer Research Network; Organization for Oncology and Translational Research
 
Joohyuk Sohn
Research Funding - AstraZeneca (Inst); Bayer (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Kenichi Inoue
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); PAREXEL/ Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - Chugai Pharma; Eisai; Lilly; Pfizer
 
Xavier Pivot
Consulting or Advisory Role - Lilly
 
Olga Nikolaevna Burdaeva
Other Relationship - Lilly
 
Meena Okera
Other Relationship - Lilly
 
Norikazu Masuda
Leadership - Japan Breast Cancer Research Group
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Lilly Japan; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Han A. Koh
Research Funding - Lilly (Inst)
 
Eva-Maria Grischke
Other Relationship - Lilly
 
Pier Franco Conte
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis; Roche/Genentech; Tesaro
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Pfizer
 
Yi Lu
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Research Funding - Lilly
Travel, Accommodations, Expenses - Lilly
 
Nadine Haddad
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Karla Hurt
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Peter A. Kaufman
Stock and Other Ownership Interests - Amgen
Honoraria - Lilly
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; Macrogenics; Merck; Pfizer; Polyphor; Roche/Genentech
Speakers' Bureau - Lilly; Teva
Research Funding - Eisai (Inst); Lilly (Inst); Macrogenics (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Lilly; Macrogenics; Polyphor
 
Antonio Llombart-Cussac
Stock and Other Ownership Interests - MedSIR
Research Funding - AstraZeneca; Eisai; Genomic Health; GlaxoSmithKline/Tesaro; Lilly; MSD; Novartis; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - MedSIR
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Genomic Health; GlaxoSmithKline/Tesaro; Lilly; Novartis; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Novartis; Pfizer; Roche
 
George W. Sledge
Leadership - Syndax; Tessa Therapeutics
Stock and Other Ownership Interests - Syndax; Tessa Therapeutics
Consulting or Advisory Role - Radius Health; Symphogen; Synaffix; Syndax; Taiho Pharmaceutical; Verseau Therapeutics
Research Funding - Genentech/Roche (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Radius Health; Tessa Therapeutics; Verseau Therapeutics